MOTS-C

What it actually is

MOTS-C is 16 amino acids long and it is encoded inside the 12S rRNA gene of the mitochondrial genome, not in nuclear DNA. Your mitochondria make it themselves. That places it in a small family called mitochondrial-derived peptides, alongside humanin and the SHLPs, and it was the first one found to work as a signalling hormone rather than a purely local molecule.

It was identified in 2015 by Changhan David Lee and colleagues at USC's Leonard Davis School of Gerontology. Circulating levels decline with age, tracking the insulin resistance, metabolic dysfunction and reduced exercise capacity that show up in older adults.

How it works

Everything runs through AMPK, the enzyme that acts as the cell's fuel gauge. When AMPK detects low energy, it switches the cell from storage mode to burning mode. Exercise activates it. Caloric restriction activates it. MOTS-C activates it too, which is where the "exercise mimetic" label comes from.

Downstream of AMPK activation: more glucose pulled into skeletal muscle through GLUT4 transporters, higher fatty acid oxidation, improved mitochondrial function and biogenesis, and better metabolic flexibility, the ability to switch cleanly between burning carbohydrate and burning fat rather than getting stuck on one.

There is a second, stranger mechanism. Under metabolic stress, MOTS-C physically relocates from the cytoplasm into the nucleus and interacts with transcription factors to change gene expression. This is retrograde signalling: the mitochondria reporting upward and instructing the cell to adapt its metabolism.

The exercise mimetic claim, honestly

In healthy humans, skeletal muscle MOTS-C spikes up to 12-fold during and immediately after exercise and stays elevated for hours. It is part of the exercise response itself, not an imitation of it.

In mice, USC's work showed treated animals doubled treadmill running capacity, improved motor coordination, and, in the finding that gets quoted most, older treated mice outperformed untreated middle-aged mice. Treated animals also resisted diet-induced obesity on a high-fat diet.

Now the correction. MOTS-C mimics the metabolic signalling of exercise. It does not replicate the mechanical part. No muscle hypertrophy, because growth requires mechanical loading. No bone density improvement, because that requires weight bearing. No cardiovascular conditioning. No neuromuscular adaptation.

The Playbook's framing is the right one: a metabolic amplifier for an active lifestyle, not a replacement for training. You still have to do the work.

What the evidence actually supports

Strong preclinical data, published in Cell Metabolism and Nature Communications. CB4211, a modified analog, has been through a Phase 1 trial. Its developer, CohBar, reported in August 2021 that it was well tolerated with no serious adverse events; the results are not posted on the registry, and we found no journal paper of them. Human observational work shows exercise raises endogenous levels and that people with diabetes and obesity have significantly lower circulating MOTS-C. A genetic variant associated with higher MOTS-C, m.1382A>C, is linked to increased longevity. It is common in East Asian populations.

What does not exist: a completed human efficacy trial, and a formal dose-finding study. The doses below come from clinical practice.

Running it

5 mg subcutaneously once weekly, or 2.5 mg twice weekly, 5 to 10 mg per week in total. Pre-workout timing is the practice convention, on the theory that it stacks with the body's own exercise-induced response. Cycles are 4–8 weeks on, 4 weeks off in the Playbook; our anti-aging and weight-loss guides describe 8–12 week cycles.

Reconstitution: a 10 mg vial with 2 mL of bacteriostatic water gives 5 mg/mL, so 5 mg is 100 units, a full U-100 syringe, and 2.5 mg is 50 units.

The honest cautions

The interaction that matters is glucose. MOTS-C enhances glucose uptake. If you take insulin or a sulfonylurea, that is a theoretical hypoglycemia risk and it warrants close blood sugar monitoring, not a shrug. Shakiness, dizziness or confusion are the signals to stop.

Active cancer is a contraindication because AMPK activation has complex effects on cell proliferation that cut both ways depending on context.

And the honest expectation-setting from the Playbook: without human efficacy trials, individual response is unpredictable. Not everyone notices anything. If four weeks pass with nothing, that is a real outcome, not a dosing error.